+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Biopharma Advances Fueling Enhanced Disease Management

  • ID: 4427748
  • Report
  • November 2017
  • Region: Global, Global
  • 250 Pages
  • Frost & Sullivan
1 of 2

This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Note: Product cover images may vary from those shown
2 of 2

Recent Biopharma Advances

  • Novel Gene Therapy for Cystinosis
  • Novel Tissue-Engineered Blood Vessel Graft
  • Big Pharma Collaboration for RNAi Therapy
  • AvidBiotics Splits to Form Two New Companies

Clinical Trial Analysis and Industry Interactions

  • Summary of Active Clinical Trials Evaluating RNAi Therapy
  • Summary of Key Contacts
Note: Product cover images may vary from those shown
3 of 2